MedTrace Logo

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

NCT03809325 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2025-04-27

No results posted yet for this study

Summary

The purpose of this study is to explore the experience with paliperidone palmitate 3-month formulation (PP3M) treatment of participants and their corresponding physicians, nurses and carers, to understand the impact of less frequent injections from their perspective.

Conditions

Interventions

DRUG

Paliperidone Palmitate 3-Month Formulation (PP3M)

No intervention will be administered as a part of this study. Participants who have been treated with PP3M in clinical practice will be enrolled.

Sponsors & Collaborators

  • Janssen-Cilag International NV

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag International NV Clinical Trial · Janssen-Cilag International NV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-21
Primary Completion
2019-07-12
Completion
2019-07-12

Countries

  • Belgium
  • France
  • Germany
  • Hungary
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03809325 on ClinicalTrials.gov